Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: The analysis of the WHO database of adverse drug reactions

European Journal of Clinical Pharmacology

Volumn 70, Issue 12, 2014, Pages 1505-1512

  Biagi, C ^a   Conti, V ^b   Montanaro, N ^a   Melis, M ^a   Buccellato, E ^a   Donati, M ^a   Covezzoli, A ^c   Amato, R ^c   Pazzi, L ^c   Venegoni, M ^b   Vaccheri, A ^a   Motola, D ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Lombardy Centre of Pharmacovigilance   (Italy)

^c CINECA   (Italy)

Author keywords

Bevacizumab; Intravitreal use; Pegaptanib; Ranibizumab; Safety profile; Spontaneous reporting database

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ADVERSE DRUG REACTION; AGE RELATED MACULAR DEGENERATION; ANEMIA; ANGINA PECTORIS; APHASIA; ARTERIOSCLEROSIS; ARTICLE; BLINDNESS; BLURRED VISION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRONCHITIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOROID HEMORRHAGE; COMPARATIVE STUDY; CONFUSION; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA EDEMA; DATA BASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIZZINESS; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELEVATED BLOOD PRESSURE; ENDOPHTHALMITIS; EYE DISEASE; EYE INFECTION; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE SWELLING; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPEREMIA; HYPERTENSION; HYPESTHESIA; HYPOPYON; INFLAMMATION; INTRAOCULAR HEMORRHAGE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOCYCLITIS; IRITIS; KIDNEY FAILURE; LUNG EMBOLISM; MACULAR DEGENERATION; MACULAR EDEMA; MALAISE; MALE; METAMORPHOPSIA; NAUSEA; PAIN; PERIPHERAL EDEMA; PHOTOPHOBIA; PNEUMONIA; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; RESPIRATORY FAILURE; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA HOLE; RETINA TEAR; RISK ASSESSMENT; SCOTOMA; STAPHYLOCOCCUS INFECTION; SUBRETINAL NEOVASCULARIZATION; THORAX PAIN; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; URINARY TRACT INFECTION; UVEITIS; VASCULAR DISEASE; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT; VITREOUS DISEASE; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VITREOUS OPACITY; VITRITIS; VOMITING; WORLD HEALTH ORGANIZATION; INTRAVITREAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; WORLD HEALTH ORGANIZATION;

EID: 84922073737     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1755-1     Document Type: Article

References (28)

1. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E et al (2013) Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: results From the GEFAL Noninferiority Randomized Trial. Ophthalmology 120(11):2300-2309
2. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2004) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg, Lasers Imaging: Off J Int Soc Imaging Eye 36(4):331-335
3. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Baha'N N (2007) Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 125(10):1357-1361
4. Chen CY, Wong TY, Heriot WJ (2007) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 143(3):510-512
5. Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114(6):1179-1185
6. Wu L, Mart-nez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81-87
7. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S (2011) Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 151(5):887-895
8. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897-1908
9. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258-1267
10. Ehlers JP (2013) The MANTA 1-year results: the anti-VEGF debate continues. Br J Ophthalmol 97(3):248-250
11. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7):1399-1411
12. Zhang XY, Guo XF, Zhang SD, He JN, Sun CY, Zou Yet al (2014) Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol 7(2):355-364
13. Ghazi NG, Kirk TQ, Knape RM, Tiedeman JS, Conway BP (2010) Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration? Clin Ophthalmol 4:307-314
14. Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G et al (2013) Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 4(1):S38-S42
15. Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146(4):508-512
16. Lucentis (2007) EPAR - Scientific Discussion, (14/03/2007). Available on: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000715/human-med-000890.jsp&mid=WC0b01ac058001d124. Accessed 10 September 2014
17. Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C (2013) Aflibercept in wet AMD: specific role and optimal use. Drug design, dev and ther 7:711-722
18. Avery RL, Alessandro AC, Nathan CS, Dilsher SD, Pieramici DJ, See R, Couvillion S et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. doi:10.1136/bjophthalmol-2014-305252
19. Authority IC (2014) Pharmaceuticals and Antitrust: the Italian Competition Authority fines Roche and Novartis over eur 180 million for cartelizing the sales of two major ophthalmic drugs, Avastin and Lucentis
20. Health IM (2014) Ministry of Heatlh - Consiglio Superiore di Sanità Sessione XLIX
21. WHO (2012) WHO collaborating centre for international drug monitoring. Uppsala Monitoring Centre, Uppsala, Sweden UMC
22. Van Puijenbroek EP, Diemont WL, van Grootheest K (2003) Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 26(5):293-301
23. Curtis LH, Hammill BG, Schulman KA, Cousins SW(2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279
24. der Reis V, Margriet I, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31(8):1449-1469
25. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M et al (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 7(8):e42701
26. Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM (2012) Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 345:e4203
27. Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D (2013) Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol 69(2):237-244
28. Huang L, Guo T, Zalkikar JN, Tiwari RC (2014) A Review of Statistical Methods for Safety Surveillance. Ther Innov Regul Sci 48(1):98-108